Entrada Therapeutics Newsroom

Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $28

Futu NewsNov 6 21:37

Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating

MT NewswiresNov 6 21:33

Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 6 20:46

Entrada Therapeutics Analyst Ratings

BenzingaNov 6 20:37

H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $20

Futu NewsNov 6 19:33

TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating

Futu NewsNov 5 23:31

TD Cowen Sticks to Its Buy Rating for Entrada Therapeutics Inc (TRDA)

TipRanksNov 5 23:11

Entrada Therapeutics Price Target Maintained With a $25.00/Share by Oppenheimer

Dow JonesAug 26 23:05

Entrada Therapeutics Analyst Ratings

BenzingaAug 26 22:55

Oppenheimer Reiterates Outperform on Entrada Therapeutics, Maintains $25 Price Target

BenzingaAug 26 22:55

Oppenheimer Initiates Entrada Therapeutics(TRDA.US) With Buy Rating, Announces Target Price $25

Futu NewsAug 26 20:32

Entrada Therapeutics Inc (TRDA) Gets a Buy From Oppenheimer

TipRanksAug 26 19:52

TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating

Futu NewsAug 14 20:33

H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $18

Futu NewsAug 14 19:31

Entrada Therapeutics Analyst Ratings

BenzingaAug 14 18:57

HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $18 Price Target

BenzingaAug 14 18:57

Buy Rating Affirmed for Entrada Therapeutics on Strong Clinical Trial Data and Regulatory Prospects

TipRanksAug 14 18:43

TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating

Futu NewsAug 14 05:31

TD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)

TipRanksAug 14 04:57

Entrada Therapeutics Analyst Ratings

BenzingaJun 25 18:52